ISSN (Print): 1389-2037
ISSN (Online): 1875-5550
Volume 19, 12 Issues, 2018
Download PDF Flyer
Open Access Funding
ISSN (Print): 1389-2037
ISSN (Online): 1875-5550
Aims & Scope
Science Citation Index ExpandedTM, Journal Citation Reports/Science Edition, Journal Citation Reports®, Index to Scientific Reviews®, Biochemistry & Biophysics Citation Index®, BIOSIS, BIOSIS Previews, BIOSIS Reviews Reports and Meetings, MEDLINE/PubMed/Index Medicus, Scopus, EMBASE/Excerpta Medica, Chemical Abstracts Service/SciFinder, ProQuest, ChemWeb, Google Scholar, BIOBASE, EMBiology, PubsHub, Genamics JournalSeek, MediaFinder®-Standard Periodical Directory, J-Gate, CNKI Scholar, Suweco CZ, TOC Premier, EBSCO and Ulrich's Periodicals Directory.
Ranking and Category:
Submit Abstracts / Manuscripts Online
Ben M. Dunn Department of Biochemistry and Molecular Biology University of Florida College of Medicine, P.O. Box 100245, Gainesville Florida, FL 32610-0245 USA
View Full Editorial Board
5 - Year: 3.105
Order Your Article Before Print
Self Archiving Policies
Instructions for Authors
Free Copies Online
Open Access Articles
Most Cited Articles
Advertise With Us
Most Accessed Articles
Most Popular Articles
Special Issue Submission
Author(s): Joseph Knoll
eISBN: 978-1-60805-470-1, 2012
This e-book is a reference on Selegiline/(-)-Deprenyl effects on the brain.
Selegiline, described in thousands of research papers, is registered in over 60 countries. At present, more than one hundred preparations containing selegiline circulate in the global market under different brand names. They are widely used in the treatment of Parkinson’s disease, Alzheimer’s disease, major depression and as a geroptotective / anti-aging drug.
(-)-Deprenyl/selegiline, the first selective inhibitor of B-type MAO which, in contrast to the known MAO inhibitors, did not potentiate the effect of tyramine but inhibited it. The compound could be combined with levodopa in Parkinson’s disease without signs of hypertensive reactions. The DATATOP study in the USA revealed that (-)-deprenyl delayed the onset of disability associated with early, otherwise untreated Parkinson’s disease. The age-related decay of the supply of the brain with phenylethylamine ( PEA), due to the progressive increase of MAO-B activity in the aging brain, and dopamine, due to the better than average decline of the dopaminergic neuronal activity during the postdevelopmental phase of life, are irresistible biochemical lesions of aging. The speed of deterioration of behavioral performances with the passing of time and longevity depends significantly on the pace of the worsening of these leasions. (-)-Deprenyl, Increasing the supply of the brain with PEA and dopamine, counteracts this aging process. Maintenance of male rats from sexual maturity until death on (-)-deprenyl delays the age-related loss of the capacity to ejaculate, slows the age-related decline of learning ability and prolongs life. In humans, maintenance from sexual maturity on (-)-deprenyl (1 mg daily) is, for the time being, the most promising prophylactic treatment to fight against the age-related decay of behavioral performances, prolonging life, and preventing or delaying the onset of age-related neurodegenerative diseases such as Parkinson’s and Alzheimer’s.
This e-book is a useful reference for graduate medical students, academic researchers in the field of neuropsychopharmacology, neurophysiology and gerontology and professional research groups in commercial organizations manufacturing selegiline preparations.
Editor(s): Shunji Wakamiya
Co-Editor(s): Kazunobu Yamauchi and Hiroyuki Yoshihara
eISBN: 978-1-60805-216-5, 2012
Organizational computing has been critical to the development of medical informatics. Many end user applications (EUAs), such as FileMaker Pro, have been applied to support medical staff work at hospitals in Japan recently.
This e-book describes how to use FileMaker Pro with hospital information systems (HISs). EUAs are described with relation to tools used for development, their functions, coordination methods with HIS, how to use them, their effectiveness, and their problems. While not all of the applications fulfill complete requirements for RASIS, and are not established, they give us new perspectives regarding HISs. This e-book also provides readers with various suggestions on how to use HISs more effectively, how to coordinate EUAs with HIS, how to manage end user applications, and how to achieve clinical effectiveness with EUAs.
This volume is specialized in the use of FileMaker Pro at hospitals and all of the developers of FileMaker Pro systems. The respective authors are medical doctors at various departments of hospitals in contrast to conventional developers who are usually unfamiliar with medical information requirements. These two features make this e-book more clinically significant and facilitate end users to handle HISs more easily.
Editor(s): Raymond J. Waller
eISBN: 978-1-60805-466-4, 2012
ISBN: 978-1-60805-568-5 ISSN: 2468-5828 (Print) ISSN: 2213-5189 (Online)
Behavior problems are approaching epidemic levels in many schools and mental health issues in school-aged children is an international concern. Similarly, parents, caregivers, and other concerned adults report behavioral disturbances in homes and in other settings despite the ongoing effort to ease access to mental health services.
Student mental health has also been demonstrated to have a direct impact on student behavior and performance. This book discusses methods by which educators can promote student mental health, similar to the ways in which schools already promote physical health.
Promoting student mental health may mean doing things differently than are currently being done, but does not involve doing more than what is already is being done. Professional educators, counselors and readers interested in public mental health matters will greatly benefit from this book.
eISBN: 978-1-68108-323-0, 2016
ISBN: 978-1-68108-324-7 ISSN: 2468-5828 (Print) ISSN: 2213-5189 (Online)
This second volume in the book series gives clear explanations of some special topics and challenges related to the roles of the school in adolescent mental healthcare (such as disability, temperament, psychological resilience, school safety and LGBT issues). Each chapter addresses beneficial and detrimental practices that schools and any involved professionals may engage in. Key features of this volume include: 1) a multidisciplinary approach to mental healthcare provision in school settings, 2) a discussion of school-based intervention in each chapter and 3) the incorporation of DSM-V standards in discussions of diagnostic criteria where applicable. This volume serves as a reference work for all educational and mental health professionals (teachers, administrators, psychologists, social workers, nurses, counselors) interested in the promotion of mental health and risk management in schools.
Editor(s): John C. Crepeau
eISBN: 978-1-60805-477-0, 2013
Most scientists and engineers are familiar with the name Josef Stefan primarily from the Stefan-Boltzmann law, which relates the amount of energy transferred by radiation to the absolute temperature raised to the fourth power. Stefan determined this law from experimental data, and it was later theoretically verified by his former student, Ludwig Boltzmann. However, it is interesting to know that this is the same Stefan who lent his name to the solid-liquid phase change problem, and concepts related to molecular diffusion and convective motion driven by surface evaporation or ablation. Stefan counted among his students Sigmund Freud, who was so inspired by his physics instructor that he incorporated scientific methods into psychoanalysis. This invaluable book details not only Josef Stefan’s original contributions in these areas, but the current state-of-the-art of his pioneering work.
Author(s): Robert E. Smith
eISBN: 978-1-60805-149-6, 2013
Medicinal Chemistry - Fusion of Traditional and Western Medicine is a textbook intended for students taking courses in the various fields of medicinal chemistry, pharmacy, medical and dental programs. Moreover, people working in the pharmaceutical industry and doctors preparing for Medical Board Exams will also find it useful. Since, new drugs are being developed by multi-disciplinary teams; this E-Book describes new paradigms that are emerging in modern biology, biochemistry and medicine. It is therefore a fusion of traditional and western medicine and between systems thinking and reductionist thinking. Readers will learn about how new drugs are investigated, developed and eventually approved by the FDA. The book also includes important information about cGMP, GLP and the FDA regulatory requirements, the importance of environmental toxins, such as bisphenol A (BPA) and perfluorooctanoic acid (PFOAA) in autoimmune diseases and health. This book offers exceptional value in its descriptions of RNA, epigenetics, toxicology, new drug development, genetically modified organisms and analytical chemistry that cannot be found in other textbooks.
eISBN: 978-1-60805-974-4, 2014
eISBN: 978-1-68108-078-9, 2015
Medicinal Chemistry - Fusion of Traditional and Western Medicine is a textbook intended for students taking courses in the various fields of medicinal chemistry, pharmacy, medical and dental programs. Moreover, people working in the pharmaceutical industry and doctors preparing for Medical Board Exams will also find it useful. Since, new drugs are being developed by multi-disciplinary teams; this E-Book describes new paradigms that are emerging in modern biology, biochemistry and medicine. It is therefore a fusion of traditional and western medicine and between systems thinking and reductionist thinking.
The 3rd edition attempts to explain the predictive, preventive, personalized and participatory (P4) paradigm of medicinal chemistry. This edition features new chapters focusing on personalized medicinal chemistry and the endocrine system (with a discussion of bioidentical hormone therapy). Other chapters cover the disease mechanism and associated pharmacology of drugs for several diseases including cancer, metabolic syndrome, diabetes, heart disease, stroke, osteoporosis, neurodegenerative diseases, the immune system and much more. The new edition also includes an overview of emergent medical problems and possible solutions (such as the flu, ebola virus, global climate change, a shortage of medicines, genetic engineering and stem cell therapy). Drugs that have been approved by the FDA since the 1st edition was written are also included. The book concludes with an explanation of systems thinking in medicinal chemistry, an important, yet rarely explored topic in other medicinal chemistry text books.
Editor(s): Kristina Johansson, Göran Lassbo and Eddy Nehls
eISBN: 978-1-60805-726-9, 2013
This discourse on the concept of the ‘new university’ encompasses a number of interconnected topics, ranging from the impacts of the market forces on the old academic territory to current perceptions about relationships between teachers and students. The book focuses on the inside features of the new academia. Some examples of issues and questions covered include:
- New media in education, which present opportunities and challenges for both learning students and teachers. But are these new possibilities for all, or just for members of the current ‘internet generation’? Moreover, How can new media be arranged to support a process of generic, collaborative learning?
- A discourse on the ‘new student’. Nowadays, terms such as rationality and ‘Bildung’ have emerged coupled with a trend for searching for shortcuts and denying one’s interests in deeper understanding of subjects. But does there really exist a new student on a qualitative level?
- Free dialogue has been brought forward by many educationalists as one important way to promote academic knowledge. How does free dialogue really contribute to this objective?
The e-book relates such issues to the specific features of the ‘new university’. For a broad insight into the issues forming the education of the future generation, Inside the New University offers important clues for the understanding of the ‘new university’ concept to readers - including educationalists and government policy makers - interested in the qualitative evolution of contemporary educational institutions.
Editor(s): Oommen P. Mathew
eISBN: 978-1-60805-728-3, 2013
Health care in the US is facing a crisis, but there is polarization and disagreement among policy makers and the public about how to solve this crisis. The overall outcome is ranked much lower than most developed nations and nearly 50 million people are uninsured. Health care is big business and is 17 % of the gross domestic product. Inside Health Care highlights the lifesaving nature of neonatal care while shining some light on what can be done to maximize neonatal well being and efficiency in healthcare access and delivery. In this book, health care issues are brought under the lens by physicians who are involved in neonatal care which gives a the reader an authentic, yet unique perspective. The contributors also offer potential solutions to highlighted issues.
Readers will be able to understand the current status of neonatal care in the US and the issues facing decision makers and the health care industry in optimizing outcomes while limiting costs.
Editor(s): Akın Eraslan Balcı
eISBN: 978-1-60805-442-8, 2013
This book focuses on the lung cancer, which is the mostly encountered, and one of the most challenging malignant disease of the world. Worldwide, the annual number of new cases of lung cancer is estimated at more than one million and is expected to increase to ten million in 2025. Fortunately, the political efforts to reduce the use of tobacco are getting increasing attention in many countries and the statistics are now showing the first positive results.
Over the last decade there have been several improvements and changes in the lung cancer management. Among the epidemiologic changes we see a change in the histopathologic pattern, with a relative decrease in squamous cell carcinoma and a rise in adenocarcinoma. Much research is attempting to identify biomarkers to predict a high risk for developing lung cancer. This will be important for implementing screening and prevention strategies. There is a steady improvement of the overall management of lung cancer based on an increasing use of combined modality therapy, consisting of surgery, chemotherapy, and radiotherapy applied concurrently or sequentially in early stage disease. Furthermore, new techniques are gaining ground, both within surgery and radiotherapy, and targeted medical therapy is being offered to more and more patients.
This book is not intended as a comprehensive textbook, but as a concise summary of advances in lung cancer clinical research and treatment for the clinician. The textbook brings up-to-date information about lung cancer, based on worldwide experience, for the use of the many physicians involved in this field.
All of the authors have been selected for their expertise and proven achievement in these challenging fields; I would like to sincerely thank all of them for participating with enthusiasm in this project. I hope that the different contributions will help the readers to fill in the gaps and stimulate them for future developments.
Editor(s): Elísio Costa
Co-Editor(s): Flávio Reis and Alice Santos-Silva
eISBN: 978-1-60805-747-4, 2013
ISBN: 978-1-60805-748-1 ISSN: 2214-6210 (Print)
The development of new erythropoietic stimulating agents (ESAs) has significantly increased in recent years. Researchers are focused on different and interesting concepts, namely, methods to increase half-life of erythropoietin (EPO), finding different routes of administration and new ESA or modified EPO molecules. Scientific literature presents evidence that EPO has other effects beyond erythropoietic stimulation. These pleiotropic effects of EPO appear to result from the existence of two different EPO receptors (EPOR) with different affinities for EPO. The discovery of new EPO actions beyond the hematopoietic system has opened a new field of investigation with these agents. Several molecules have been developed to present the protective action, without the activation of the hematopoietic system. These agents can be potentially used in several diseases of the brain/central and peripheral nervous system, eye, heart and kidney.
This volume of Frontiers in Drug Discovery includes a revision of articles on erythropoiesis and EPO gene regulation, microRNAs and their potential contribution to the development of new therapeutic strategies, animal models for studying kidney disease-associated anemia as well as benefits/risks of ESA therapy. The biological effects of new ESA molecules, heparin-binding erythropoietin and of pHBSP, and the potential applications of ESA, are also elicited in this volume.
This volume is, therefore, a useful reference for medicinal chemists and hematologists interested in drug development and medicine related to ESAs.